zheimer disease (AD) is characterized by deposits of an aggregated 42-amino-acid P-amyloid peptide (I3AP) in the brain and cerebrovasculature. After a concentration-dependent lag period during in vitro incubations, soluble preparations of synthetic .8AP slowly form fibrillar aggregates that resemble natural amyloid and are measurable by sedimentation and thioflavin T-based fluorescence. Aggregation of soluble flAP in these in vitro assays is enhanced by addition ofsmall amounts ofpre-aggregated gamyloid "seed" material. We also have prepared these seeds by using a naturally occurring reaction between glucose and protein amino groups resulting in the formation of advanced "glycosylation" end products (AGEs) which chemically crosslink proteins. AGE-modified flAP-nucleation seeds further accelerated aggregation of soluble flAP compared to non-modiflied "seed" material. To better understand the factors which contribute to amyloid formation and stability, we have studied the in vitro aggregation of soluble synthetically prepared PAP monomers, a process which displays nucleation-dependent kinetics, especially at physiological (nanomolar) concentrations of monomer (refs. 9 and 10; this report). Although millimolar concentrations of (3AP exhibit extensive aggregation within minutes, micromolar and lower concentrations of monomer display a concentration-dependent lag period during which little or no measurable aggregate is formed, followed by a "growth" phase of more rapid aggregation (9-11). This lag period can be eliminated by adding trace amounts of preformed aggregate as "seed" material which serves to immediately induce aggregation (9) . Seeding apparently eliminates the need for de novo formation of aggregation nuclei, a much slower process than the subsequent growth of nucleated aggregates. Thus, amyloid seeds can be seen to represent critical protein masses with special structural features capable of nucleating the formation of larger insoluble aggregates of amyloid from pools of soluble P3AP. The nature of these structural characteristics is unknown, but the net result of seeding is significant acceleration in the rate of aggregation compared with unseeded incubations of soluble PAP. By extrapolation from this simple in vitro model to the similar nanomolar concentrations of soluble fAP found in cerebrospinal fluid in vivo, it might be expected that the deposition and accumulation of PAP as amyloid plaques would reflect, in part, the amount or availability of seed material able to nucleate aggregation. Some cases of AD might correspondingly arise as a consequence of increased availability of nucleation seeds in the disease-prone brain relative to normal counterparts not destined to suffer AD at a similar chronological age.
gregates that resemble natural amyloid and are measurable by sedimentation and thioflavin T-based fluorescence. Aggregation of soluble flAP in these in vitro assays is enhanced by addition ofsmall amounts ofpre-aggregated gamyloid "seed" material. We also have prepared these seeds by using a naturally occurring reaction between glucose and protein amino groups resulting in the formation of advanced "glycosylation" end products (AGEs) which chemically crosslink proteins. AGE-modified flAP-nucleation seeds further accelerated aggregation of soluble flAP compared to non-modiflied "seed" material. Over time, nonenzymatic advanced glycation also results in the gradual accumulation of a set of posttranslational covalent adducts on long-lived proteins in vivo. In a standardized competitive ELISA, plaque fractions of AD brains were found to contain about 3-fold more AGE adducts per mg ofprotein than preparations from healthy, age-matched controls. These results suggest that the in vivo half-life of fi-amyloid is prolonged in AD, resulting in greater accumulation of AGE modifications which in turn may act to promote accumulation of additional amyloid.
Alzheimer disease (AD) is the major cause of dementia and the fourth leading cause of death in the United States, affecting 10%o of the population age 65 and older. In combination with gradual cognitive decline, AD is characterized by the progressive accumulation of neurofibrillary tangles, amyloid plaques, and cerebrovascular amyloid deposits in the brain. Typically, 5-to 10-fold greater numbers of amyloid plaques accumulate in the brains of AD patients than in age-matched healthy controls. These amyloid plaques mainly comprise aggregated copies of a 42-amino-acid (-amyloid peptide (PAP; ref. 1) , which derives by cleavage from a family of larger amyloid peptide precursor proteins (2, 3) .
Although the amount of aggregated PAP or 3-amyloid may directly relate to the increased release of soluble 8lAP in some rare genetically linked forms of familial AD (4) (5) (6) , the levels of soluble SlAP in cerebrospinal fluid of sporadic AD cases are similar to those in age-matched healthy counterparts (7, 8) . If increased levels of soluble PAP monomers generally fail to account for the increased numbers ofamyloid plaques seen in the majority of AD patients, then the increased amyloid in AD must instead reflect an increase in the rate of aggregation and amyloid formation, a decreased rate of amyloid degradation, or some combination of both.
To better understand the factors which contribute to amyloid formation and stability, we have studied the in vitro aggregation of soluble synthetically prepared PAP monomers, a process which displays nucleation-dependent kinetics, especially at physiological (nanomolar) concentrations of monomer (refs. 9 and 10; this report). Although millimolar concentrations of (3AP exhibit extensive aggregation within minutes, micromolar and lower concentrations of monomer display a concentration-dependent lag period during which little or no measurable aggregate is formed, followed by a "growth" phase of more rapid aggregation (9) (10) (11) . This lag period can be eliminated by adding trace amounts of preformed aggregate as "seed" material which serves to immediately induce aggregation (9) . Seeding apparently eliminates the need for de novo formation of aggregation nuclei, a much slower process than the subsequent growth of nucleated aggregates. Thus, amyloid seeds can be seen to represent critical protein masses with special structural features capable of nucleating the formation of larger insoluble aggregates of amyloid from pools of soluble P3AP. The nature of these structural characteristics is unknown, but the net result of seeding is significant acceleration in the rate of aggregation compared with unseeded incubations of soluble PAP. By extrapolation from this simple in vitro model to the similar nanomolar concentrations of soluble fAP found in cerebrospinal fluid in vivo, it might be expected that the deposition and accumulation of PAP as amyloid plaques would reflect, in part, the amount or availability of seed material able to nucleate aggregation. Some cases of AD might correspondingly arise as a consequence of increased availability of nucleation seeds in the disease-prone brain relative to normal counterparts not destined to suffer AD at a similar chronological age.
In the present communication, we explore the possibility that the formation or stability of amyloid structures which seed PAP aggregation may be enhanced by covalent crosslinks that chemically polymerize components of the aggregate. Under physiological conditions, long-lived proteins become markedly modified and extensively crosslinked by advanced "glycosylation" end products (AGEs). AGEs result from the spontaneous, nonenzymatic glycation reactions between proteins and reducing sugars (12) , including for instance the ubiquitous monosaccharide glucose, which is the primary energy source used by the brain. Initially in the process of advanced glycation, condensation reactions between reducing sugars and protein amino groups form a population of readily reversible Schiff bases, some of which rearrange over days into more stable Amadori products. Over weeks and months, these early products chemically evolve by additional rearrangement, dehydration, cleavage, and addition reactions into a widely heterogeneous set of covalently bound adducts known collectively as AGEs. The accumulation of such AGEs in vivo mainly depends on the bioavailability of susceptible primary amino groups, the ambient concentration of reducing sugars, and the half-life of the modified protein. Accordingly, AGE modifications are strikingly evident on very long-lived proteins such as lens crystallins, nerve myelin, and matrix collagen; are markedly enhanced in diabetic patients (13) (14) (15) ; and might well be expected to accumulate on the aggregated proteins of AD and other amyloidoses.
By accumulating slowly over time, the AGE modifications that appear on proteins in vivo not only serve as an index of protein half-life but also can initiate a variety of biological effects mediated both by cellular receptor systems for AGEmodified ligands (16) and by processes which depend on the inherent chemical reactivity of both nascent and late AGE moieties (17) . As a first step in understanding the potential consequences of AGE accumulation on f3-amyloid in AD, we investigated the effects of advanced glycation on the aggregation of P3AP monomers in vitro. Our data indicate that advanced glycation ofH3AP accelerates aggregation of soluble PAP and that small amounts of preformed AGE-modified (3AP seeds more efficiently nucleate the further merging of (3AP peptides into insoluble aggregates than does nonglycated seed material. We also report that purified plaque fractions from AD brains contain more AGE adducts per mg of protein than do parallel fractions prepared from healthy age-matched controls, further underlining the potential physiological and pathogenic importance of AGE-regulated SAP aggregation and amyloid accumulation. (18) . Briefly, fluorescence of aggregates added to 10 ,uM thioflavin T (Aldrich) in 50 mM potassium phosphate buffer at pH 6.0 was measured upon excitation at 450 ± 5 nm, with emission detected at 482 ± 10 nm on a Perkin-Elmer LS-50B spectrofluorimeter. Where indicated, small amounts of preformed aggregates ("nucleation seeds") were added to the monomeric PAP and 0.1 M sodium acetate.
MATERIALS AND METHODS
Lysines at positions 16 and 28 of 8AP contain primary amino groups which may react with reducing sugars to generate AGEs. Monomeric I3AP-(1-40) (250 uM) and 0.2 M sodium phosphate buffer (pH 7.5) were incubated with or without 1 M glucose at 37TC for 4 months to generate preformed aggregates of glycation-modified PAP, referred to as "AGE-P3AP seed" or "PAP seed," respectively. After incubation, protein concentrations of seed preparations were measured and adjusted with buffer to 150 uM final concentration. By competitive ELISA (19) , AGE-I3AP seed contained 50 AGE units/mg of protein and HAP seed contained <0.5 AGE unit/mg of protein. Indicated amounts of glucose and/or aminoguanidine, a potent inhibitor of advanced glycation and crosslink formation (20) , were also added to solutions of 3AP before sodium acetate in some experiments.
Aggregation of physiological concentrations of SAP was quantitated by the method of Burdick et aL (11) . Synthetic preparations of IAP-(1-40) were labeled with 125I (NEN) and chloramine-T (Sigma) for 1 min before the reaction was quenched with 10 mM tyrosine/50 mM sodium metabisulfite. Unincorporated label was removed by filtration through a Sephadex G-10 column equilibrated with 0.5x phosphate buffered saline (PBS) at pH 7.4. The 125I-labeled 3AP (specific activity, -3 x 106 cpm/pg) was immediately diluted to 5 nM final concentration in the presence of various seeds, glucose, and/or aminoguanidine at the indicated concentrations. After various incubation periods at 370C, aggregation reaction mixtures were underlaid with 20%6 sucrose/0.1 M sodium acetate at the same pH as the incubation, centrifuged for 30 min at 50,000 x g, and frozen in liquid nitrogen. Each microcentrifuge tube was cut and the bottom 5-mm section, representing the aggregated, sedimentable fraction which had pelleted through the sucrose cushion, was analyzed for radioactivity in a 'y counter. The remainder of the tube and liquid were also analyzed. The amount of aggregate formed was calculated as a percentage: (pellet cpm/total cpm) X 100.
Measurement of AGEs by Competitive ELISA. Aliquots of frozen samples of prefrontal cortex (Broadman areas 9 and 10) from patients with or without behaviorally and neuropathologically confirmed AD were suspended in 10 volumes (per wet weight) of 2% sodium dodecyl sulfate/0.1 M 2-mercaptoethanol and Dounce homogenized. The homogenates were boiled for 10 min and then centrifuged at 10,000 X g for 10 min. Supernatants were aspirated and the resulting pellets were washed and recovered three times with PBS at 10,000 x g for 10 min. In some experiments, this crude plaque fraction was further washed twice with 4 tion of 10 nM 125I_3AP-(1-40) monomer in 0.1 M sodium acetate at pH 7.0 increased slowly over a 2-day incubation (Fig. 3) . When 10 nM labeled monomer was incubated with 200 nM unlabeled SAP seed material, the amount of sedimentable label was similar to the no-seed, monomer-only curve. In contrast, incubation of 10 nM monomer with 200 nM AGE-,SAP seed increased the amounts of sedimentable label compared with the pAP-seed and no-seed experimental points. Thus, the amount of labeled SAP associated with sedimentable aggregates observed in incubations of PAP monomer with AGE-pAP seed was greater than that seen in incubations with PAP seed or no seed under conditions in which pH and soluble 8AP concentrations were physiological.
Glucose Modifies Kinetics of Aggregation. In the process of advanced glycation, formation of a Schiff base between glucose and a protein amino group precedes subsequent maturation of Amadori products into AGE-modified PAP.
Aminoguanidine is a compound which prevents AGE formation following initial glucose reactions with protein amines (20) . Incubation of 400 uM pAP-(1-28) in 0.1 M sodium acetate (pH 7.0) with 100 mM glucose stimulated fluorescentaggregate formation when compared with parallel incubations of monomer, monomer plus aminoguanidine, or monomer plus aminoguanidine plus glucose (Fig. 4) . Separate incubations of glucose or aminoguanidine failed to generate any detectable fluorescent signals.
AGE Content of Brain Fractions. On average, plaqueenriched fractions isolated from samples of frontal cortex of 10 AD brains contained significantly more AGE modifications than did corresponding preparations from 7 healthy controls (8.9 ± 1.4 versus 2.7 ± 0.5 AGE units/mg ofprotein, P = 0.002; see Fig. 5 ). The average chronological age of both the AD and control groups was 77 years. The presence of AGEs in similar fractions of parietal cortex from AD and normal brains has also been observed (data not shown). Supernatant fractions of sodium dodecyl sulfate-soluble proteins from AD and control brains routinely contained <0.1 AGE unit/mg of protein. 
